Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report

BACKGROUND: Nintedanib is a multi-target receptor tyrosine kinase inhibitor. In two recent randomized phase 3 trials (INPULSIS™-1 and -2), it has been shown to slow the disease progression of idiopathic pulmonary fibrosis (IPF) by reducing the decline in the forced vital capacity (FVC). Although the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Satoshi, Sekine, Akimasa, Baba, Tomohisa, Yamakawa, Hideaki, Morita, Masato, Kitamura, Hideya, Ogura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778330/
https://www.ncbi.nlm.nih.gov/pubmed/26940352
http://dx.doi.org/10.1186/s12890-016-0201-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778330/
https://www.ncbi.nlm.nih.gov/pubmed/26940352
http://dx.doi.org/10.1186/s12890-016-0201-9

Ejemplares similares